Accès ouvert déclaré2026article
Airway clearance management for bronchiectasis in China: a multicentre cross-sectional study from the Chinese bronchiectasis registry (BE-China)
Yang Liu, Yifan Wu, Yuan-lin Song, Wei-Jie Guan, Xiang‐Huai Xu, Hai-Wen Lu, Hai-Yan Ge, Rong-Chang Chen, Rong-Chang Chen, Jin‐Fu Xu, Bin Wu, Ling-Wei Wang, Xiao-Dong Lv, Jie-Ming Qu, Hong Luo, Jian Feng, Yuan-Yuan Li, Jinguang Jia, Wei-Qiang Mo, Lin Liu, Hongyan Gu, Jing-Bo Jiang, Dao-Xin Wang, Bin Wang, Li Li, Wen Li, Zhijun Jie, Min Xie, Li, Dan, 1971-, Xiaoyun Fan, Zhi Yuan, Xinlun Tian, Min ZHANG, Hong Fan, Jian He, Chunling Du, Chao Cao, De-Jie Chu, Jian-Quan Zhang, Jingmin Deng, Yu Chen, Feng Gan-zhu, Xiao-Lin Chen, Li Fan, Yun-Hui Zhang, Jingqing Hang, Feng-Ying Zhang, Xiong‐biao Wang, Xu-Ming Luo, Yu-Ping Li, Liang Dong, Tao Ren, Qing-Wei Meng, Yanliang Ma, Qin Jia, Yang, Zhao, 1970-, Chang-Xi Zhang, Peng-Fei Wang, H. Wang, Hao Tang, Bei He, Ning Shen, Cui-Xia Zheng, Fei Xu, Xiaoqun Ye, Kejing Ying, Li-Min Wang, Yu Li, De-Dong Ma, Yang-Dan Zou, Jian-Ying Zhou, 胡芬, Xin Yao, Ya-Hong Sun, Jun Wang, Xiaoyan Jin, Bin Cao, Jie Huang, Li, Jing, 1957-, Changming Wang, Bing Li, Wei Jia, Xian-Mei Zhou, Gao Xi-wen, Zhenzhong Su, Yong Lin, Qiao Zhang, Wan‐Li Ma, Wei-Ning Xiong, Xia-Hui Ge, Yiming Zeng, Bi-Wen Mo, Miao Luo, Xian‐Ling Lu, Xiao-Lian Song, Xin Su, Xuedong Liu, Wei Wei Wang, Shaofeng Zhan, Qun Lv, Xiao-Ju Zhang, Wei Zhang, Jian-An Huang, Min Chen, Dan-Ting Zhan, Xiao-Long Ma, Min Zhou, Yun Feng, Zhi-Yao Bao, Ting Guo, Liang Ding, Zhao Bing-rong, Hui Ma, Hai-Qin Wang, Guo-Hang Yuan, Juan Ge, Chen Huang, Xin-Yu Deng, Guo-Ping Zhang, Jing-Yi Huang, Yan-Xiong Mao, Zhou-Fang Mei, Li-Juan Hua, Hong-Ying Sun, Xue-Shuang Cao, Ao-Hua Wu, Fengming Ding, Lai‐jian Cen, Xiang Tong, Zhuo-Zhe Li, Qiaoli Zhang, Lei Zhou, Jing Yang, Feng-Xia Guo, Yanmei Huang, Xuan Wei, Ye Lu, Kai-li Deng, Xun Xu, Xiao-Qiong Tan, Zhi-Ting Gao, Xia-Yi Miu, Da-Peng Dong, Qian Qi, Zhan-Xia Li, Hong Qing, Yu-Qian Li, Jing Chang, Xiu-Hua Kang, Hongtao Sun, Rui-qing He, Kang-Li Yang, Yu Na Jin, Bei-Bei Liu, Zhi-Fang Wang, Ying-Ying Long, Yong Zhou, Man Luo, Jian-Yu Peng, Pan-feng Xu, Wen-Jing Liu, Ya-Qi Meng, Xingxing Zhu, Ting Zhang, Jing Zhang, Zhi-Bo Liu, Jun Xu, Qiang Chen, Hui-Ping Qin, Zhang, Feng, 1962 Aug. 29-, Jie Lin, Jie Xu, Meng-Meng Wang, Chun-Lan Chen, Wang, Qi, 1971-, Jian-Nan Zhu, Min-Min Chen, Xiao-Rong Wang, Yun Jun-jie, Jun-Wei Hong, FengChi, Xiao-Yang Chen, Huang-Cui Li, Jing-Xue Hong, Hongying Wang, Ying Liu, Jing Liu, Jiang-Wei Ma, Hui-Ting Huang, Ze-Hai Xia, Lijun Shen, Jian-Zi Su, Nan Su
0Citations signalées
11Institutions associées
1Pays d’affiliation
Résumé fourni par la source
Background: Airway clearance techniques (ACTs) are guideline-recommended in bronchiectasis, while contemporary patterns and determinants of ACTs adoption remain unclear in China. Methods: A multicentre cross-sectional study was conducted using data from the BE-China cohort between 10 Jan 2020 and 31 Mar 2024. Clinical characteristics and prespecified ACT modalities were collected across 92 hospitals. Multivariable logistic regression identified important associations of ACTs utilization. Findings: Among 9647 patients, 12.2% (1177) used regular ACTs at baseline, and regional heterogeneity in ACTs utilization was observed. Moreover, ACTs users exhibited prolonged disease duration, a higher proportion of severe disease, greater comorbidity, heavier cough and sputum burden, and more frequent pharmacological and ventilatory interventions. Variables associated with increased ACTs utilization included comorbid burden (OR 1.47, 1.28-1.70; p < 0.0001), daily sputum (OR 1.68, 1.33-2.10; p < 0.0001), expectorants usage (OR 3.19, 2.74-3.71; p < 0.0001), inhaled antibiotics (OR 2.04, 1.35-3.07; p = 0.00065), macrolide therapy (OR 2.31, 1.78-2.99; p < 0.0001), other long-term oral antibiotics (OR 1.37, 1.13-1.66; p = 0.0013), noninvasive ventilation requirement (OR 4.11, 3.14-5.39; p < 0.0001), and disease duration (per SD increase, OR 1.08, 1.01-1.15; p = 0.027). Both BE-China and the similar European Bronchiectasis Registry (EMBARC) cohorts showed distinct etiological and comorbidity profiles, yet consistently revealed a higher medication burden among ACTs users. Interpretation: In China, ACTs utilization is primarily concentrated among patients with bronchiectasis who have a heavier symptom burden and greater treatment intensity. Clinicians may leverage the identified associations to optimize adherence and guide phenotype-targeted ACTs implementation strategies, and these findings may serve as a reference for future research. Funding: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Innovation Program of Shanghai Municipal Education Commission, Program of Shanghai Municipal Science and Technology Commission, Major Project of Guangzhou National Laboratory.
Sujets associés
Cystic Fibrosis Research AdvancesGastroesophageal reflux and treatmentsChronic Obstructive Pulmonary Disease (COPD) Research